Revance reports Q3 EPS ($1.63), consensus (90c)

Reports Q3 revenue $56.8M, consensus $60.38M. “The third quarter marked an important period for Revance as we evolved our pricing strategy for DAXXIFY to incorporate real-world experience and customer feedback gathered during our early roll out. We are encouraged by the response we’ve received from our customers with regards to the price change and believe this adjustment will help us drive deeper penetration and greater adoption over time. While early, we are seeing a positive impact on DAXXIFY reorder rates and purchase volumes and continue to believe that our innovative and differentiated products will allow us to be a meaningful player in the facial injectables market.. We are also excited to have initiated our cervical dystonia PrevU program which is making great progress and allowing us to gain important real-world feedback from providers, patients and payers – all of which will be key to informing our commercial launch in 2024. Further, with our focus on capital allocation priorities and our strong cash position, we believe we have the necessary resources to support the growth of both of our aesthetics and therapeutics franchises while achieving positive Adjusted EBITDA in 2025,” said Chief Executive Officer Mark Foley.